Roth Capital Initiates Alcobra Pharma With Buy

Analysts at Roth Capital initiated coverage on Alcobra Pharma ADHD with a Buy rating. The target price for Alcobra Pharma is set to $40. Alcobra Pharma shares have surged 24.43% over the past 52 weeks, while the S&P 500 index has gained 12.93% in the same period. Alcobra Pharma's shares dropped 3.33% to close at $17.42 yesterday.